Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Senard

Showing results (11-20 of 140) with videos related to

Pageof 14
Sort By:
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|June 1, 1996
The discovery of vasomotor nervesJ L Montastruc, O Rascol, J M Senard
Neuroscience and Biobehavioral Reviews|July 1, 1997
Glutamate antagonists and Parkinson's disease: a review of clinical dataJ L Montastruc, O Rascol, J M Senard
Lancet (London, England)|January 20, 1996
Neuroprotection in Parkinson's diseaseJ L Montastruc, O Rascol, J M Senard
Movement Disorders : Official Journal of the Movement Disorder Society|September 24, 1999
Treatment of Parkinson's disease should begin with a dopamine agonistJ L Montastruc, O Rascol, J M Senard
Drugs|September 1, 1993
Current status of dopamine agonists in Parkinson's disease managementJ L Montastruc, O Rascol, J M Senard
Annales Medico-Psychologiques|April 1, 1986
[Psychogenic polydipsia with hyponatremia]L Schmitt, J M Senard, P Montastruc, et al.
L'Encephale|July 2, 2002
[Biological factors of PTSD: neurotransmitters and neuromodulators]P Birmes, J M Senard, M Escande, et al.
European Journal of Pharmacology|November 20, 1990
Identification of alpha 2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cellsJ M Senard, D Langin, L Estan, et al.
Clinical Neuropharmacology|January 1, 1986
Mesulergine (CU 32-085) in the treatment of Parkinson's diseaseA Rascol, J L Montastruc, O Rascol, et al.
Therapie|March 1, 1994
[Physiological mechanisms of cardiovascular adaptation to orthostatism. Role of the sympathetic nervous system and pharmacological implications]J L Montastruc, J M Senard, P Verwaerde, et al.
Pageof 14

Showing results (11-20 of 140) with videos related to

Sort By:
Pageof 14
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|June 1, 1996
The discovery of vasomotor nervesJ L Montastruc, O Rascol, J M Senard
Neuroscience and Biobehavioral Reviews|July 1, 1997
Glutamate antagonists and Parkinson's disease: a review of clinical dataJ L Montastruc, O Rascol, J M Senard
Lancet (London, England)|January 20, 1996
Neuroprotection in Parkinson's diseaseJ L Montastruc, O Rascol, J M Senard
Movement Disorders : Official Journal of the Movement Disorder Society|September 24, 1999
Treatment of Parkinson's disease should begin with a dopamine agonistJ L Montastruc, O Rascol, J M Senard
Drugs|September 1, 1993
Current status of dopamine agonists in Parkinson's disease managementJ L Montastruc, O Rascol, J M Senard
Annales Medico-Psychologiques|April 1, 1986
[Psychogenic polydipsia with hyponatremia]L Schmitt, J M Senard, P Montastruc, et al.
L'Encephale|July 2, 2002
[Biological factors of PTSD: neurotransmitters and neuromodulators]P Birmes, J M Senard, M Escande, et al.
European Journal of Pharmacology|November 20, 1990
Identification of alpha 2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cellsJ M Senard, D Langin, L Estan, et al.
Clinical Neuropharmacology|January 1, 1986
Mesulergine (CU 32-085) in the treatment of Parkinson's diseaseA Rascol, J L Montastruc, O Rascol, et al.
Therapie|March 1, 1994
[Physiological mechanisms of cardiovascular adaptation to orthostatism. Role of the sympathetic nervous system and pharmacological implications]J L Montastruc, J M Senard, P Verwaerde, et al.
Pageof 14